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Abstract
Estrogen receptor (ER) positive breast cancer is frequently sensitive to endocrine therapy. Multiple mechanisms of endocrine
therapy resistance have been identified, including cancer stem-like cell (CSC) activity. Here we investigate SFX-01, a
stabilised formulation of sulforaphane (SFN), for its effects on breast CSC activity in ER+ preclinical models. SFX‐01
reduced mammosphere formation efficiency (MFE) of ER+ primary and metastatic patient samples. Both tamoxifen and
fulvestrant increased MFE and aldehyde dehydrogenase (ALDH) activity of patient-derived xenograft (PDX) tumors, which
was reversed by combination with SFX‐01. SFX-01 significantly reduced tumor-initiating cell frequency in secondary
transplants and reduced the formation of spontaneous lung micrometastases by PDX tumors in mice. Mechanistically, we
establish that both tamoxifen and fulvestrant induce STAT3 phosphorylation. SFX-01 suppressed phospho‐STAT3 and SFN
directly bound STAT3 in patient and PDX samples. Analysis of ALDH+ cells from endocrine-resistant patient samples
revealed activation of STAT3 target genes MUC1 and OSMR, which were inhibited by SFX-01 in patient samples. Increased
expression of these genes after 3 months’ endocrine treatment of ER+ patients (n= 68) predicted poor prognosis. Our data
establish the importance of STAT3 signaling in CSC-mediated resistance to endocrine therapy and the potential of SFX-01
for improving clinical outcomes in ER+ breast cancer.
Introduction
Three out of four cases of breast cancer (BC) express the
estrogen receptor alpha (ER) and are treated with endocrine
therapies, such as selective ER modulators (e.g., tamox-
ifen), aromatase inhibitors (e.g., letrozole), and selective ER
down-regulators (e.g., fulvestrant) [1]. However, despite the
undoubted success of endocrine treatments, distant BC
recurrences and death occur at a steady rate for at least 15
years after the 5–10 year treatment period is completed [2].
This finding stresses the need for new approaches that can
provide long-term disease-free survival.
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Endocrine resistance hampers the cure of ER+ BC, and
therefore major efforts have been employed to address the
mechanisms. Acquired resistance can be mediated by
modulation of ER activity through its mutation, by up-
regulation of ER coactivators (e.g., FOXA1), by activation
of mitogenic signaling pathways (e.g. MAPK, PI3K/AKT)
induced by receptor tyrosine kinase activity (e.g., EGFR,
HER2) or by overexpression of substrates for cyclin-
dependent kinases (CDKs) [3, 4]. Several drugs targeting
these pathways have been tested in clinical studies, and
recently CDK4/6 kinase inhibitors have been shown to
increase overall survival (OS) of patients with advanced
ER+ BC and three (palbociclib, ribociclib and abemaciclib)
are now FDA approved [5–7].
Cancer stem cells (CSCs) can be responsible for tumor
initiation and growth and are more resistant than non-CSCs
to cancer therapies, such as chemo- and radiotherapy [8]. We
and others have shown that breast CSCs (measured by the
percentage of ALDH+, or mammosphere-forming cells)
are not targeted by endocrine therapies in ER+ BC [9–11].
This leads to enrichment in cells with breast CSC activity
which are dependent upon developmental signaling path-
ways, such as Notch and Wnt [12, 13]. Eradication of
endocrine-resistant CSCs is likely to provide long-term dis-
ease-free survival but so far none of the approved drugs for
patients with ER+ tumors has been shown to target CSCs.
Sulforaphane (SFN), an isothiocyanate found in cruci-
ferous vegetables, has demonstrated activity against breast
CSCs [14], although clinical application has been hampered
due to its inherent physicochemical and biological
instability [15]. In order to improve its stability, SFX‐01,
SFN formulated within an alpha-cyclodextrin complex, has
been developed [16].
Here, we report that SFX‐01 used in combination with
endocrine therapies prevents breast CSC enrichment in
patient samples and PDX tumors in vivo, and mechan-
istically it directly targets STAT3 to inhibit its activity in
endocrine resistance. STAT3 activation in patient primary
tumors measured by expression of STAT3-induced genes
predicts resistance to endocrine treatments.
Results
SFX-01 reduces breast CSC activity in primary and
metastatic ER+ breast cancer patient derived-
samples
Mammosphere forming efficiency (MFE) and ALDH1
enzymatic activity have previously been shown to be a
characteristic of breast CSCs [17, 18], which can be targeted
by SFN in BC cell lines [14]. SFX-01 (SFN stabilised in
alpha-cyclodextrin complex, Fig. S1a) reduced MFE in 13 of
16 patient-derived ER+ tumor samples (Fig. 1a and Sup-
plementary Tables 1 and 2 for patient and tumor character-
istics). Next, we assessed CSC activity following SFX-01 pre-
treatment of cells from patients with endocrine-resistant BC.
SFX-01 reduced the percentage of ALDH+ cells in all six
samples (and by >60% in five; Fig. 1b) and also significantly
decreased MFE in four of these samples (Fig. 1c). These data
suggest that short term SFX-01 treatment targets breast CSC
activity in patient-derived and endocrine-resistant cells.
We then investigated the effect of SFX-01 on MFE of
patient-derived ER+ tumor cells cotreated with tamoxifen.
SFX-01 remained effective and significantly reduced MFE
in combination with tamoxifen in eight out of ten samples
tested (Fig. 1d). In addition, we tested 3-day pre-treatment
of ER+ cell lines (MCF-7, T47D, and ZR-75-1) with
tamoxifen or fulvestrant in combination with SFX-01. Both
ALDH activity and MFE were reduced by SFX-01 in all
cell lines confirming reversal of the breast CSC activity that
is induced by short-term treatment with antiestrogen drugs
(Fig. S1b, c). Moreover, we have confirmed that the effects
on MFE and ALDH positivity of commercially available
SFN are comparable to the effects of SFX-01 at equivalent
molar sulforaphane concentration (data not shown).
SFX-01 prevents tamoxifen enrichment for cells with
cancer stem cell properties in patient-derived
xenograft tumors
To better model the clinical scenario of our treatments, two
ER+ patient-derived xenograft (PDX) models were grown
subcutaneously in NSG mice, one from an early (HBCx34,
[19]) and another from a metastatic tumor (BB3RC31,
[20]). We assayed proliferation and breast CSC activity in
these PDX models after 14-day in vivo treatment with either
SFX-01, tamoxifen, or combination of both drugs (Fig. 2a).
We observed that tamoxifen treatment decreases the pro-
liferation marker Ki67 and tumor growth in both PDX
models and SFX-01 reduced tumor growth in the HBCx34
model, but had no significant impact on BB3RC31 (Figs. 2b
and S2a). However, breast CSC activity measured by
ALDH enzymatic activity or MFE was increased by
tamoxifen and decreased by SFX-01, both alone and in
combination with tamoxifen (Fig. 2c, d). We then per-
formed in vivo limiting dilution transplantation of HBCx34
PDX cells derived from tumors previously treated with
tamoxifen and/or SFX-01. Cells from tumors treated with
SFX-01 could not form any tumors on reimplantation of
4,000 cells, in contrast with cells from tumors treated with
vehicle control or tamoxifen alone (Fig. 2e). Graphs
representing tumor size observed in all serial dilutions are
shown in Fig. S2b. Overall, tumors treated with SFX-01 had
reduced tumor-initiating cell frequency confirming that
SFX-01 targets breast CSC activity in vivo (Fig. 2e).
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SFX-01 inhibits PDX tumor growth, prevents CSC
activity and prevents spontaneous metastasis to the
lungs
To further validate the in vivo effects of combining SFX-01
with antiestrogens on CSC activity we treated HBCx34
PDX cells for 56 days with either tamoxifen or fulvestrant
(Fig. 3a). As expected, both antiestrogens strongly reduced
the number of proliferative cells measured by Ki67
expression (Fig. 3b) whilst increasing both ALDH activity
and MFE (Fig. 3c, d). SFX-01 had no effect on proliferation
(Fig. 3b) but significantly inhibited antiestrogen stimulated
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breast CSC activity (Fig. 3c, d). A 56-day treatment of the
second PDX model (BB3RC31) also demonstrated that the
antiestrogen enrichment of breast CSCs can be reduced by
SFX-01 (Fig. S3a, b). Over the 8-week treatment period,
tamoxifen plus SFX-01 significantly suppressed tumor
growth versus tamoxifen alone in the HBCx34 (Fig. 3e) but
not the BB3RC31 PDX models (data not shown). On the
other hand, fulvestrant treatment maintained tumor growth
suppression at 8 weeks and no additive effect was seen with
SFX-01 in either HBCx34 (Fig. 3f) or BB3RC31 (data not
shown) PDX models.
We next investigated whether treatments had an effect on
PDX spontaneous lung metastases. Using a human-specific
mitochondrial antibody we could clearly observe micro-
metastases in the lungs from mice bearing HBCx34 PDX
tumors treated with tamoxifen or fulvestrant (Fig. 3g, h). In
contrast, lungs from HBCx34 mice treated with tamoxifen
or fulvestrant in combination with SFX-01 were free from
micrometastases, although disseminated tumor cells per-
sisted (Fig. 3g, h). In the BB3RC31 PDX model SFX-01
reduced micrometastases by 50% in combination with ful-
vestrant but no effect was seen in combination with
tamoxifen (Fig. S3c, d), suggesting SFX-01 hinders colo-
nisation of the lungs by disseminated tumor cells in sensi-
tive tumors.
SFX-01 targets STAT3 signaling, which is activated
by antiestrogen therapy
We next sought to determine the mechanism of sensi-
tivity to SFX-01. The direct binding targets of SFN have
been assessed in BC cell lines, identifying STAT3 and
NF-κB subunits among the top high-affinity targets [21].
STAT3 was a particularly interesting target since ALDH
+ breast CSCs and tamoxifen resistant cells have pre-
viously been shown to express higher levels of phospho-
STAT3 (active form), and inhibition of STAT3 reduces
ALDH+ cell numbers and tumorigenicity [22, 23].
HBCx34 PDX tumors treated in vivo for 56 days with
tamoxifen or fulvestrant showed increased phospho-
STAT3 expression which was inhibited by cotreatment
with SFX-01 (Fig. 4a). In the BB3RC31 PDX model we
also observed that fulvestrant, but not tamoxifen,
increased phospho-STAT3 expression and SFX-01 only
reduced phospho-STAT3 levels in fulvestrant-treated
tumors (Fig. S4b). We also assessed whether phospho-
NF-κB p65 was modulated in a similar way to STAT3
but overall its expression did not change in either
HBCx34 or BB3RC31 PDX treated tumors (Fig. S4a, b).
Next, we examined STAT3 activation in an HBCx34
PDX model that has been selected for tamoxifen resis-
tance, which we previously demonstrated to display
enrichment of breast CSCs [12]. Increased phospho-
STAT3 was seen compared with the parental endocrine-
sensitive HBCx34 PDX model and this was reversed by
treatment with SFX-01 (Fig. 4b). Pull-down experiments
with an activity-based probe (ABP) of SFN [21] in
HBCx34 PDX tumor cells confirmed direct interaction of
SFN with STAT3 in both antiestrogen and vehicle-
treated tumors (Fig. 4c), establishing STAT3 as the likely
target of SFX-01.
Next we tested whether SFX-01 inhibited STAT3 sig-
naling in antiestrogen resistant patient samples. Cells from
metastatic sample BB3RC61 treated with SFX-01 showed
a significant reduction in phospho-STAT3 expression
compared with tamoxifen or fulvestrant treatments alone
(Fig. 4d). Furthermore, we observed direct binding of the
sulforaphane activity-based probe (SFN-ABP) to STAT3
in cells from this same patient sample (Fig. 4e). Analysis
of four additional antiestrogen resistant metastatic sam-
ples confirmed that SFX-01 combined with either
tamoxifen or fulvestrant inhibited STAT3 activity in three
of these patient samples (BB3RC44, BB3RC66, and
BB7103), though SFX-01 only inhibited fulvestrant-
induced STAT3 activation in BB3RC66 sample
(Fig. S4c). Interestingly, SFX-01 did not repress STAT3
activity in sample BB7121 that had previously been
treated clinically with SFX-01 (STEM trial). This
patient’s disease had progressed in the presence of
SFX-01 and was thus resistant to it.
On the whole, we have established, using PDX models
in vivo and patient samples in vitro, that SFX-01 targets
STAT3 and can inhibit its activity that is induced by
treatment with antiestrogens.
Fig. 1 SFX-01 reduces breast CSC activity in primary and meta-
static ER+ breast cancer patient derived-samples. aMammosphere
formation efficiency (MFE) of freshly isolated ER+ early (primary)
and metastatic (pleural effusions and ascites) patient-derived samples
cultured in the presence of SFX-01 (5 μM) or vehicle control. MFE
data for each individual patient sample is represented. MFE was
determined on days 7–9 and calculated by dividing the number of
mammospheres formed (≥50 μm diameter) by the original number of
single cells seeded (500 cells/cm2) and is expressed as the mean per-
centage of mammosphere formation. b Percentage of ALDH-positive
cells in six ER+ metastatic BC patient-derived samples. Cells were
grown in low-adherent plates in the presence of SFX-01 (5 μM) or
water (control) for 72 h and then subjected to ALDEFLUOR assay.
Arrows indicate a reduction greater than 60% compared with control.
Representative FACS plots of ALDEFLUOR assay are shown.
ALDH-positive cells were discriminated from ALDH-negative cells
using the ALDH inhibitor, DEAB. c Percentage of MFE in six ER+
metastatic BC patient-derived samples. Cells were pre-treated in low-
adherent plates in the presence of SFX-01 (5 μM) or water (control) for
72 h and then plated for MFE colony assay without drugs. Repre-
sentative micrographs of mammospheres are shown. d Percentage of
MFE of ER+ early (primary) and metastatic patient-derived samples
treated with control (water and ethanol), SFX-01 (5 μM), tamoxifen
(1 μM) or a combination of SFX-01 with tamoxifen. MFE data are
represented as mean percentage ± SEM. *p < 0.05; **p < 0.01.
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Fig. 2 SFX-01 prevents tamoxifen enrichment for cells with cancer
stem cell properties in patient-derived xenograft tumors. a
BB3RC31 and HBCx34 patient derived xenografts (PDXs) treated
in vivo for 14 days with SFX-01 (300 mg/kg/day, oral gavage) in the
presence or absence of tamoxifen (10 mg/kg/day, oral gavage).
HBCx34 model was kindly provided by Dr Elisabetta Marangoni
(Institute Curie, Paris). Vehicle control used was 1% carbox-
ymethylcellulose dissolved in distilled water. b Quantification of Ki67
expression determined by immunohistochemistry showing that
tamoxifen but not SFX-01 significantly decreases proliferation marker
Ki67. c Percentage of ALDH-positive cells was determined with
ALDEFLUOR assay. ALDH-positive cells were discriminated from
ALDH-negative cells using the ALDH inhibitor, DEAB. Mouse cells
were excluded from the FACS analysis with anti-mouse MHC Class I
(H-2Kd) antibody. d Mammosphere formation efficiency was deter-
mined on days 7–9 and calculated by dividing the number of mam-
mospheres formed (≥50 μm diameter) by the original number of single
cells seeded (500 cells/cm2) and is expressed as the mean percentage of
mammosphere formation. Representative micrographs are shown.
e Secondary transplantation of 500, 100, 20, and 4 K cells after in vivo
treatments. Experiment was carried out in NSG mice with 90-day
slow-release estrogen pellets. Tumor growth (>75 mm3) was assessed
at day 90 and is represented as mice positive for growth/mice tested for
each cell number tested. ELDA of tumor-initiating cell frequency is
shown. Data are represented as mean ± SEM. *p < 0.05; **p < 0.01.
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STAT3-related genes are up-regulated in antiestrogen
resistant ALDH+ cells and are associated with worse
outcomes for ER+ breast cancer patients
To investigate which genes are regulated by STAT3 in the
antiestrogen resistant ALDH+ CSC population, we com-
pared the gene expression profile between ALDH+ and
ALDH− cells of four metastatic ER+ patient samples
treated with endocrine therapy prior to analysis (Fig. S5a)
[24]. Ingenuity Pathway Analysis (IPA) demonstrated dif-
ferential expression (fold change ≥2) of 28 STAT3-related
genes that were all up-regulated in ALDH+ cells (Fig. 5a).
Next, we hypothesised that this 28-gene STAT3 signature
of ALDH+ cells could predict prognosis of patients diag-
nosed with ER+ BC. In published gene expression micro-
array datasets from 762 ER+ tumors (KM plotter, [25]), we
found that elevated expression of the 28 STAT3-related
genes before treatment was significantly associated with BC
recurrence (Fig. 5b). Thus, activation of STAT3 signaling in
ER+ tumors is associated with more aggressive disease.
We therefore tested whether SFX-01 could reduce
expression of the top four STAT3 related genes in ER+
antiestrogen resistant patient samples, and we found that
two of the genes (OSMR and MUC1) were significantly
down-regulated by SFX-01 treatment (Fig. 5c). Based on
these findings, we investigated if failure to reduce expres-
sion of these two STAT3 genes with antiestrogen treatments
was associated with worse outcomes due to STAT3
activation in a 68-patient matched dataset [26] before and
after 3 months treatment with an aromatase inhibitor.
Remarkably, increase in the sum of these two genes (OSMR
and MUC1) upon antiestrogen treatment was significantly
associated with decreased BC specific survival (Fig. 5d).
The change in expression of each of these genes individu-
ally was not significantly associated with outcome (data not
shown).
Thus, persistent activation of the STAT3 signaling
pathway after antiestrogen treatment could potentially be
used as a biomarker to predict endocrine resistance and,
hence, to identify the patient group most likely to benefit
from STAT3 inhibition with SFX-01 therapy.
Discussion
In this study, we establish that SFX-01 targets antiestrogen
resistant breast CSCs in patient samples and PDXs. Com-
pared with antiestrogen treatment alone, SFX-01 combined
with antiestrogen drugs significantly reduced ALDH+
CSCs, their sphere-forming activity and tumor-initiating
cell frequency, as well as formation of lung micrometastases
in PDX tumors grown in mice. Mechanistically, both
tamoxifen and fulvestrant induced STAT3 phosphorylation
although not always to the same degree in individual
tumors. We show that SFX-01 suppresses this adaptive
STAT3 phosphorylation and establish that an ABP of SFN
directly binds to and targets STAT3 in cells from patient
samples and PDX tumors. Importantly, analysis of ALDH+
cells from endocrine-resistant patient samples revealed
activation of STAT3 signaling and expression of STAT3
target genes MUC1 and OSMR, which were down-regulated
by SFX-01 in patient samples. Moreover, increased
expression of these two genes after 3 months’ endocrine
treatment predicted poor prognosis in patients with ER+
tumors. We propose that inhibiting STAT3 signaling with
SFX-01 may help to overcome endocrine therapy resistance
and recurrence in ER+ BC.
We previously reported that CSC activity is increased by
the antiestrogens tamoxifen and fulvestrant, both in vitro
and in vivo [12], and others have demonstrated a role for
SFN in targeting breast CSCs in vitro with concentrations
ranging 0.5–5 μM [14]. Here, we show that a stabilised form
of SFN, SFX-01, is a potent inhibitor of endocrine resistant
CSCs using an equivalent dose of 5 μM. In contradistinction
to the previous report that used cell lines [14], we establish
that STAT3, not Wnt signaling, is the primary target
mechanistically responsible for endocrine resistance of
breast CSCs in human breast tumors.
STAT3 activation has been associated with ALDH
expression and MFE in triple negative BC cell lines [23, 27]
and recently it has been shown that a STAT3 inhibitor
Fig. 3 SFX-01 prevents CSC activity of PDX cells treated with
tamoxifen and fulvestrant. SFX-01 inhibits tumor growth com-
pared with tamoxifen alone and prevents formation of micro-
metastases in the lungs. a HBCx34 PDX treated in vivo for 56 days
with tamoxifen (10 mg/kg/day, oral gavage) or fulvestrant (200 mg/kg/
week, subcutaneous injection) in the presence or absence of SFX-01
(300 mg/kg/day, oral gavage). Vehicle control used was 1% carbox-
ymethylcellulose in combination with a weekly subcutaneous injection
of the fulvestrant vehicle. b Quantification of Ki67 expression deter-
mined by immunohistochemistry. c Percentage of ALDH-positive cells
was determined with ALDEFLUOR assay. ALDH-positive cells were
discriminated from ALDH-negative cells using the ALDH inhibitor,
DEAB. Mouse cells were excluded from the FACS analysis with anti-
mouse MHC Class I (H-2Kd) antibody. d Mammosphere formation
efficiency was determined on days 7–9 and calculated by dividing the
number of mammospheres formed (≥ 50μm diameter) by the original
number of single cells seeded (500 cells/cm2) and is expressed as the
mean percentage of mammosphere formation. e–f Tumor growth of
HBCx34 PDX tumors treated in vivo for 56 days. Individual tumors
(n= 10) treated with tamoxifen (e) or fulvestrant (f) are represented by
squares and tumors treated in combination with SFX-01 are repre-
sented by triangles. Red line shows average tumor growth for
tamoxifen (e) or fulvestrant (f) and blue line shows average tumor
growth for the combination treatment with SFX-01. g–h Mice lungs
were stained with anti-human mitochondrial antibody and micro-
metastases with at least 10 cells were counted. Percentage of mice
bearing micrometastases for each tamoxifen (g) and fulvestrant (h)
treatment group is shown. Data are represented as mean ± SEM. *p <
0.05; **p < 0.01.
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blocking phosphorylation can target breast CSCs in ER+
palbociclib-resistant cell lines [28]. We previously reported
that Notch4 signaling is increased in antiestrogen resistant
ALDH+ breast CSCs [12], and using a tamoxifen-resistant
MCF7 sub-line, an association between Notch4 and STAT3
activation was established [22]. However, we have not
confirmed here that STAT3 phosphorylation is confined to
the ALDH+ population. The relevance of our finding is
strengthened by demonstrating that STAT3 is activated in
both antiestrogen treated PDX tumors and patient-derived
samples.
The recent finding that SFN bound directly to STAT3
with high-affinity in BC cell lines [21] led us to investigate
STAT3 as the target in antiestrogen treated PDX and
endocrine resistant patient-derived samples. We show con-
vincingly that binding occurs and, since SFN is known to
react with cysteine residues [29], future research is war-
ranted to determine precisely which STAT3 cysteine
residues are targeted by SFN. We also show that SFX-01
reduces the phosphorylation of STAT3 in vitro and in vivo,
in short-term antiestrogen treatment and established resis-
tance. This demonstrates its utility and provided a rationale
for its use in clinical trials in patients, where plasma levels
of about 1 µM SFN are achieved following SFX-01
administration (data not shown). Therefore, we recently
recruited 47 patients with metastatic ER+ BC who were
progressing on endocrine therapy and showed that the
addition of SFX-01 to the endocrine therapy resulted in
clinical benefit in 25% of patients [30]. Our in vivo data
demonstrate where primary tumor phospho-STAT3 is
reduced, there is a reduction in metastatic lung colonisation.
This indicates that SFX-01 could reduce distant recurrence
rates in early BC.
In order to better target STAT3-driven endocrine resis-
tant BC, we analysed gene expression in samples from
advanced BC patients who had received prior endocrine
Fig. 4 SFX-01 targets
STAT3 signaling, which is
activated by antiestrogen
therapy. a phospho-STAT3 and
total STAT3 protein expression
levels determined by Western
Blot in HBCx34 PDX treated
in vivo for 56 days with
tamoxifen or fulvestrant in the
presence or absence of SFX-01.
β-actin was used as a reference
for the loading control. b Protein
expression levels in tamoxifen-
resistant (TAMR) HBCx34 PDX
treated in vivo for 56 days with
SFX-01. c Total STAT3 protein
detection before and after SFN-
ABP pull-down experiments in
HBCx34 PDX treated tumors.
GAPDH was used as a reference
for the loading control. d Protein
expression levels in metastatic
patient-derived sample
BB3RC61 treated for 72 h with
tamoxifen or fulvestrant in the
presence or absence of SFX-01.
e Total STAT3 protein detection
before and after SFN-ABP pull-
down experiments in
BB3RC61 sample. GAPDH was
used as a reference for the
loading control.
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therapy. We derived a STAT3 signature consisting of 28
genes that was associated with poor progression-free sur-
vival of ER+ BC patients. Importantly, two of the most
expressed genes, OSMR and MUC1, were down-regulated
by SFX-01 treatment of patient-derived samples. Our results
support these effects on OSMR or MUC1 being most likely
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mediated by SFX-01 inhibition of STAT3 but we cannot
rule out possible direct effects of SFX-01 on these two
genes. Interestingly, OSMR STAT3-mediated transcription
has recently been shown to be regulated by miRNA 551b-
3p in BC cells [31], while STAT3 transcriptional activation
of MUC1 occurs through a direct association with a
STAT3-binding site in the MUC1 promoter [32]. OSMR
and MUC1 were both STAT3-responsive and SFX-01-
sensitive in patient samples, and their increased expression
after 3 months’ endocrine treatment accurately predicted
survival over a 14 year period after surgery for BC. These
data suggest that this two-gene signature could have
potential to select tumors responsive to SFX-01, which
would have to be confirmed in a larger group of patients.
OSMR has already been associated with worst prognosis
although not specifically for ER+ tumors [33], and an
association between OSMR signaling and reduced ER
levels has been reported [33]. Moreover, in silico data of
breast tumors shows a significant relationship between
OSMR and markers of CSCs [34] and OSMR signaling
increases invasive capacity of BC cell lines [35]. In addi-
tion, MUC1 has been shown to contribute to the self-
renewal of BC cells inducing MFE [36], ALDH activity
[37], and tamoxifen resistance [38], as well as predicting
failure to tamoxifen treatment [39].
Thus, overall we establish the potential of SFX-01 for
clinically meaningful improvements to endocrine therapy in
ER+ BC by inhibiting STAT3 signaling and reversing
CSC-mediated resistance. The derivation of a STAT3
pathway signature that predicts poor prognosis and resis-
tance to endocrine therapy indicates that a subpopulation of
ER+ breast tumors might be the rational targets for SFX-01
therapy in combination with current endocrine therapies.
Materials and methods
Breast cancer patient-derived samples
Early BC samples were collected from patients undergoing
surgical resection of the primary tumor at three NHS
Foundation Trusts (South Manchester, Salford Royal, and
The Pennine Acute Hospitals). Metastatic fluids (ascites or
pleural effusions) drained from advanced BC patients were
collected at the Christie and South Manchester Hospitals
NHS Foundation Trusts through the Manchester Cancer
Research Centre Biobank. Fully informed consent from all
patients was obtained in accordance with local National
Research Ethics Service guidelines (study numbers: 05/
Q1402/25, 05/Q1403/159, and 12/ROCL/01). Early and
metastatic BC samples were processed as described pre-
viously [12, 20]. Supplementary Tables 1 (early BC) and
two (metastatic BC) present the clinico-pathological char-
acteristics of the samples used in this study.
In vivo experiments using patient-derived
xenografts
All in vivo studies were carried out in accordance with the
UK Home Office (Scientific Procedures) Act 1986 under
project licence PPL40/3645. NOD scid gamma (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ, NSG) and athymic Nude (Foxn1nu)
mice (Charles River) were used in the following experi-
ments. Small fragments of HBCx34 (early) and BB3RC31
(metastatic) BC PDX tumors were implanted sub-
cutaneously into the flanks of 8–12-week-old female NSG
mice. These two preclinical models are estrogen-dependent,
so animals were administered with 8 μg/ml 17-beta estradiol
(Sigma-Aldrich, #E2758) in drinking water at least 4 days
previously to implantation until the end of the experiment.
HBCx34 PDX model and their endocrine resistant variant
(tamoxifen-resistant, TAMR) were kindly provided by Dr
Elisabetta Marangoni (Institut Curie, Paris) [19]. In vivo
experiments with HBCx34 TAMR PDX model were carried
out using Nude mice in the Institut Curie. For clinical
details of BB3RC31 refer to [12, 20].
When average PDX tumor volume reached
200–300 mm3, mice were randomized between treatment
groups ensuring that all groups had similar starting mean
tumor volumes. All in vivo experiments were performed
with a minimum of n= 3 mice per condition. Tumor size
and animal weight were recorded twice weekly in a blinded
manner. SFX-01 (Evgen Pharma PLC, 300 mg/kg/day) and
tamoxifen citrate (Sigma-Aldrich, #T9262, 10 mg/kg/day)
Fig. 5 STAT3-related genes are up-regulated in antiestrogen
resistant ALDH+ cells and are associated with worse outcomes for
ER+ breast cancer patients. a Heatmap illustrating the 28 STAT3-
related genes differentially expressed in ALDH+ cells of four ER+
metastatic patient-derived cells treated with antiestrogen treatments
(fold change ≥2, pairwise Rank Products). Red color represents gene
up-regulation while blue shows down-regulation in ALDH+ relative
to ALDH- cells. b Kaplan–Meier analysis of high versus low
expression of STAT3 28-gene signature showing recurrence-free sur-
vival in ER+ breast cancer patients. The gene expression data is from
published microarray datasets available in KM plotter [25].
c Expression of OSMR, CTTN, MUC1, and PBX1 genes was assessed
by real-time qPCR analysis and normalized to control to calculate fold
change. Metastatic patient-derived cells were treated for 72 h with
SFX-01 (5 μM) or water (control). d Heatmap showing OSMR and
MUC1 gene expression in patient matched dataset after 3 months
treatment with letrozole relative to baseline. Heatmap is ranked from
left to right using the sum of the expression of the two genes. Red
indicates up-regulation and blue indicates down-regulation in treated
tumors relative to baseline. All significant cut-points (p ≤ 0.05) are
shown in gray. The Kaplan–Meier plot demonstrates that elevated
expression of these genes is significantly associated with decreased
breast cancer specific survival (BCS). Vertical bars on survival curves
indicate censored cases. p value is based on a log-rank
(Mantel–Cox) test.
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were administered by oral gavage (0.1 ml/dose) on a 5 day
from 7 day basis (weekends excluded) for 14 or 56 days;
whereas Fulvestrant (200 mg/kg/week, Astrazeneca) was
injected subcutaneously (0.1 ml/dose) on a weekly basis for
56 days. SFX-01 and tamoxifen citrate were made in 1%
carboxymethylcellulose (Sigma-Aldrich, #C9481) dissolved
in distilled water. SFN levels were measured in the mice
plasma achieving a concentration of about 2 µM (data not
shown), which is an appropriate approximation of the
in vitro dose used (5 µM) since SFN is rapidly metabolized
in vivo [40]. Upon termination, PDX tumors were collected
in ice-cold DMEM media and processed as described in
[12] for further downstream analyses. Mouse lungs were
formalin-fixed paraffin-embedded for histological assess-
ment of metastatic disease.
In vivo limiting dilution assays were performed to
evaluate tumor initiation ability of HBCx34 PDX after
2 weeks of in vivo treatment. Xenografts treated with either
SFX-01, tamoxifen citrate, combination or vehicle control
for 14 days were collected and digested using collagenase-
hyaluronidase (Stem Cell Technologies) to obtain single-
cell suspensions. Serial limiting dilution of PDX-derived
cells (500,000; 100,000; 20,000; 4,000 cells) were resus-
pended in mammosphere media:Matrigel (1:1) and sub-
cutaneously injected into the flank of NSG mice (n= 4 per
condition). The 90-day slow-release estrogen pellets were
implanted subcutaneously 2 days prior to cell injection
(0.72 mg, Innovative Research of America). At day 90 after
cell injection, positive tumor growth was considered in mice
bearing a tumor greater than 75 mm3. The tumor-initiating
cell frequency was calculated using Extreme Limiting
Dilution Analysis software (The Walter and Eliza Hall
Institute of Medical Research) with a 95% confidence
interval. p values were obtained by Chi-squared statistical
analysis.
Mammosphere colony assay
Cancer stem cell activity using the mammosphere colony
assay was determined following the protocol described
elsewhere [41]. Freshly isolated cells from ER+ primary
and metastatic patient-derived samples (500 cells/cm2) were
cultured for 7–9 days in mammosphere culture conditions.
When indicated, cells were either treated directly in the
mammosphere media or pre-treated for 72 h in low adher-
ence previously to assess their mammosphere forming
ability. PDX-derived cells (500 cells/cm2) were cultured for
7–10 days. Cell lines were pre-treated in adherence for
3 days and then cultured in suspension for 5 days (200 cells/
cm2). Mammosphere formation efficiency (MFE, %) was
calculated by dividing the number of mammospheres
formed per well (≥50 μm diameter) by the number of single
cells seeded per well. MFE is expressed as the average
percentage of MFE.
ALDEFLUOR assay
Cancer stem cell activity was measured using the ALDE-
FLUOR assay (Stem Cell Technologies). This fluorescent
reagent system allows detecting the activity of aldehyde
dehydrogenase (ALDH), enzyme highly active in mammary
stem cells [17]. The assay was performed following the
manufacturer’s instructions. Single cells were resuspended
in ALDEFLUOR assay buffer containing 1.5 mM bodi-
pyaminoacetaldehyde, ALDH substrate, and incubated in
the dark for 45 min at 37 °C. In parallel, a fraction of the
cells was incubated in the presence of a twofold molar
excess of the ALDH inhibitor, diethylaminobenzaldehyde
(DEAB), in order to correct for background staining and
define the ALDH-positive region during the analysis. When
using PDX tumors, a Pacific Blue anti-mouse H-2Kd MHC
Class I antibody (BioLegend, #116616) was used to remove
mouse cells from the analysis. In all cases, dead cells were
excluded using 7-aminoactinomycin D (7AAD, BD Bios-
ciences). Data were acquired with the BD LSRII flow cyt-
ometer (BD Biosciences) and analysed using the BD
FACSDivaTM software.
Western blot
Cells were lysed and samples prepared for Western blot as
explained in [12], detailed steps are shown in Supplemen-
tary Materials and Methods. Primary antibodies used were:
Phospho-STAT3 Y705 (Cell Signaling, #D3A7), STAT3
(Cell Signaling, #124H6), phospho-NFκB p65 S536 (Cell
Signaling, #93H1), NFκB (Cell Signaling, #D14E12),
β-actin (Sigma-Aldrich, #A2228).
Affinity pull-down assays
SFN-ABP was prepared and used in affinity pull-down
assays following the approach described in [21]. Further
details can be found in Supplementary Materials and
Methods.
Immunohistochemistry
Formalin-fixed paraffin-embedded PDX tumors and mouse
lung tissue were cut into 4 μm-thick sections for immu-
nohistochemical analysis. Sections were stained for either
human Ki67 (Dako, #M7240) [12] or anti-human mito-
chondrial antibody (Abcam, #ab92824) [20]. Further
details are included in Supplementary Materials and
Methods.
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Gene expression analysis of ALDH+/− populations
in ER+ metastatic breast cancer
Whole transcriptomic datasets for ALDH+ and ALDH−
populations from ER+ metastatic patient-derived samples
were available here [24]. Briefly, ER+ advanced BC
patients were drained of metastatic fluids (ascites or
pleural effusions) due to discomfort. Breast cancer cells
were isolated following the methodology described else-
where [20] and then stained using the ALDEFLUOR
assay. After FACS sorting, RNA was extracted and the
whole transcriptome of ALDH+ and ALDH- populations
was assessed using Affymetrix Whole-Transcript Human
Gene 1.0 ST Array (Affymetrix, Thermo Fisher Scientific)
[24]. Four patient samples were selected on the basis of
being ER+ PR+ HER2− and having received endocrine
treatment prior to collection. Differentially expressed
STAT3-related genes (upstream and downstream) between
ALDH+ and ALDH− cells were identified using IPA
(Qiagen).
Quantitative real-time PCR
Six metastatic patient-derived samples were treated in
adherence for 72 h in the presence of 5 μM SFX-01 or water
(vehicle control) in DMEM/F-12 GlutaMAX medium
(GIBCO) containing 10% fetal bovine serum (FBS; GIBCO),
10mg/ml insulin (Sigma-Aldrich), 10mg/ml hydrocortisone
(Sigma-Aldrich), and 5 ng/ml epidermal growth factor (EGF;
Sigma-Aldrich). Total RNA was then extracted as described
in [12]. RNA quality, integrity, and concentration were
assessed using the Qubit RNA HS assay and the Agilent
Bioanalyzer. Gene expression was evaluated with the 48.48
IFC Dynamic Arrays (Fluidigm Corporation) using standard
Taqman Assays as per protocol (see Supplementary Materi-
als and Methods for further information).
Statistical analysis
Unless otherwise stated, statistical analyses were carried out
by a two-tailed Student’s t test. A p value ≤ 0.05 was con-
sidered to be statistically significant. Error bars represent the
standard error of mean (SEM) of at least three independent
experiments. Data are shown as mean ± SEM.
Survival analysis was performed on patient datasets
using either the KM plotter online tool [25] or performing
Cox proportional hazards tests for all possible points-of-
separation using the survivALL R package [42].
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